10 May 2022: Original Paper
Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study
Bruno Roche 1BCDE , Artur Bauhofer 2ACDEF* , Miguel Ãngel Gomez Bravo 3BCDE , Georges Philippe Pageaux 4ABCDE , Fabien Zoulim 5BDE , Alejandra Otero 6BC , Martin Prieto 78BC , Carmen Baliellas 9BC , Didier Samuel 1ACDEDOI: 10.12659/AOT.936162
Ann Transplant 2022; 27:e936162
Table 4 Characteristics of patients with HBV recurrence.
| Patient no. | Time to HBV recurrence [months] | Determination of HBV recurrence | Risk factors before/at time of LT | Antiviral treatment at time of HBV recurrence | HCC recurrence after LT | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clinical signs | HBsAg [IU/mL]* | HBV DNA [IU/mL]* | Viral co-infection | HBsAg [IU/mL] | HBeAg [IU/mL] | HBV DNA [IU/mL] | sc HBIg dose/ interval | Anti-HBs [IU/L] | NUC | |||
| 1 | 18.5 | None | + | ND | None | + | ND | ND | 500 IU/ biweekly | 108.2 | TDV | Yes |
| 2 | 23.5 | None | + | ND | HDV | + | ND | ND | 500 IU/ every 10 days | 22.6 | ETV | No |
| 3 | 34.6 | Not doc | ND | 12 | None | 2156 | ND | 20 | 500 IU/ every 5 weeks | 167.9 | ETV | No |
| 4 | 21.8 | Not doc | + | ND | None | 57 | NA | ND | 500 IU/ weekly | 100.1 | TDV | Yes |
| 5 | 13.1 | Not doc | 28 | ND | HDV | 8500 | ND | ND | 500 IU/ biweekly | 29 | ETV | No |
| 6 | 15.0 | Not doc | 199 | ND | HDV | NA | ND | ND | 500 IU/ monthly | NA | ETV | No |
| 7 | 13.2 | Not doc | + | NA | None | 3159 | ND | ND | 500 IU/ every 3 weeks | NA | TDV | Yes |
| * Values at time of first identification of HBV recurrence after LT. ETV – entecavir; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; HCC – hepatocellular carcinoma; HDV – hepatitis D virus; IU – international unit; LT – liver transplantation; NA – not available; ND – not detectable; Not doc – not documented; NUC – nucleos(t)ide analog; TDV – tenofovir. | ||||||||||||